EARNINGS AND TRADING: Hargreaves Services results beat guidance
The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
----------
Hargreaves Services PLC - Durham, England-based provider of services for environmental, infrastructure and property sectors - Reports results for the year ended May 31. Revenue rises 33% to £351.4 million from £264.4 million the year before, beating market expectations of £288.2 million. Pretax profit more than doubles to £40.3 million from £17.5 million, while underlying pretax profit surges 93% to £34.0 million from £17.6 million, beating guidance for £33.4 million. Proposes 20.5 pence per share final dividend, up 11% from 18.5p. Company "remains confident" in its prospects, saying its Services division has "strong momentum" going into the new year, as well as "a substantial contract base and excellent visibility of future revenues, supported by continued demand across the group's core markets of connectivity, clean energy and environmental services." Adds that Hargreaves Land "remains well placed to realise further value from its property portfolios".
----------
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Private portfolio company Yarrow Bioscience completes merger with public company VYNE Therapeutics Inc, and concurrent private financing worth approximately USD200 million. Says Yarrow is RTW Investments LP's seventh new company creation and is advancing potential first-in-class anti-thyroid stimulating hormone receptor antibody YB-101, which is designed to treat Graves' disease and thyroid eye disease and has fast-track designation from the US Food & Drug Administration. RTW Bio invested USD5.9 million in Yarrow's series A funding, and a further USD2.4 million in the PIPE financing occurring concurrently with the merger. Says the combined company operates as Yarrow Bioscience Inc and began trading on Nasdaq on Tuesday. RTW Bio saw a 192% uplift to carrying value based on Yarrow's closing share price on Tuesday, equivalent to USD20.4 million or 2.0% of net asset value as at June 30.
----------
Avon Technologies PLC - Wiltshire, England-based military protection equipment maker - Confirms that Team Wendy Ceradyne has received a follow-on delivery order worth USD20.1 million from the Defense Logistics Agency under the second-generation advanced combat helmet framework contract announced in February, 2022. "Over the past three years, we have worked hard to strengthen Team Wendy through continuous improvement, investing in our people and building operations and manufacturing excellence," comments Chief Executive Officer Jos Sclater. "As execution and delivery performance continue to improve, we are seeing that progress reflected in growing customer confidence. This follow-on order is a strong endorsement of the improvements we have made and reinforces our position on the ACH GEN II programme."
----------
PayPoint PLC - Welwyn Garden City, England-based payment services provider - Reports results for the first quarter ended June 30. Net revenue decreases 6.4% to £39.5 million from £42.2 million the year before, with Network Services revenue falling 6.5% to £21.6 million from £23.1 million. Digital Payments & Open Banking revenue rises 4.1% to £3.2 million from £3.1 million. Merchant Services revenue falls 6.1% to £7.7 million from £8.2 million, and Love2shop revenue falls 9.8% to £7.0 million from £7.8 million. "We have had a busy start to the year and, in the first quarter, achieved our primary objective of implementing the changes arising from our business reorganisation," comments CEO Nick Wiles, continuing: "Our underlying business performance for the quarter was consistent with our expectations and, against a strong prior year comparator, has established a solid platform for the year ahead. This performance was delivered against the backdrop of a trading environment that remained challenging, with subdued consumer activity and confidence alongside a weak overall economy." Wiles adds that PayPoint remains confident it will make further progress in the current year and meet market expectations. Company will hold a Capital Markets Day on September 29.
----------
Ecora Royalties PLC - London-based critical minerals-focused royalty company with interests in the Americas, Europe and Africa - Issues trading update for the second quarter of 2026. Reports total contribution of USD19.0 million, up approximately 60% from USD11.8 million the year before. Net debt is "down materially" at USD74.9 million as of June 30, from USD124.6 million one year prior. Company expects further deleveraging throughout the rest of this year, with CEO Marc Bishop Lafleche saying this will provide "balance sheet flexibility to fund further royalty acquisitions that meet our investment criteria." Lafleche also says: "Q2 was a strong quarter, with the producing critical minerals portfolio continuing to demonstrate its cash generation potential." Ecora's base metals portfolio contributed USD14.1 million, more than doubled from USD5.3 million the year before.
----------
Allergy Therapeutics PLC - West Sussex, England-based biotechnology company focused on allergy immunotherapies - Expects to report £59.9 million in revenue for the year ended June 30, up 9% or approximately 5% at constant currency, from £55.0 million the year before. Also expects £23.6 million in revenue for the second half, saying that commercial momentum is accelerating, up by over 12% from £21.0 million the year before and accelerating from growth of 7% in the first half. Cash totals £24.2 million as at June 30, up from £12.8 million one year prior. Company says this follows the repayment of all outstanding shareholder loans and the drawdown of new secured funding from Hayfin. Reports annual revenue growth exceeding 4% in Germany and 12% growth in Spain. Says German performance is positive given the ongoing transition away from unregistered products under Germany's TAV programme, and that Grassmuno's launch in January missed the peak September to February treatment season. Allergy Therapeutics "is strongly positioned for a further acceleration in sales momentum," expecting the current financial year "to be the first to benefit from a full high season of [Grassmuno's] availability." Also expects double-digit revenue growth for the current year.
----------
Copyright 2026 Alliance News Ltd. All Rights Reserved.